目前用于戒烟的药物治疗方法和正在临床试验中的新药。
Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials.
机构信息
Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunokicho, Chuo-ku, Kobe, Hyogo 650-0017, Japan.
Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Chuo-ku, Kobe, Hyogo, Japan.
出版信息
Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619875925. doi: 10.1177/1753466619875925.
Smoking causes various diseases and is a major public health threat worldwide. Therefore, promoting smoking cessation is the most important intervention contributing to maintaining the health of smokers and nonsmokers and saving enormous financial expense. We reviewed existing and emerging smoking-cessation pharmacotherapies from the Cochrane Database of Systemic Reviews, PubMed, Ovid, and ClinicalTrials.gov databases. A literature review revealed that bupropion may be appropriate for patients interested in reducing smoking who dislike, or who have failed, nicotine-replacement therapy (NRT). Additionally, varenicline and NRT are efficacious first-line smoking cessation treatments and should be given to all individuals unless contraindicated.
吸烟可引起多种疾病，是全球主要的公共卫生威胁。因此，促进戒烟是维护吸烟者和不吸烟者健康以及节省大量财政费用的最重要干预措施。我们从 Cochrane 系统评价数据库、PubMed、Ovid 和 ClinicalTrials.gov 数据库中检索了现有的和新兴的戒烟药物治疗方法。文献回顾显示，对于那些不喜欢或已经对尼古丁替代疗法（NRT）失败的有意愿减少吸烟的患者，安非他酮可能是合适的选择。此外，伐尼克兰和 NRT 是有效的一线戒烟治疗方法，除非有禁忌症，否则应给予所有个体。
Zotero 插件